Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gunning, W. T.
Right arrow Articles by Pereira, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gunning, W. T.
Right arrow Articles by Pereira, M. A.
[Cancer Research 62, 4199-4201, August 1, 2002]
© 2002 American Association for Cancer Research


Advances in Brief

Chemoprevention by Lipoxygenase and Leukotriene Pathway Inhibitors of Vinyl Carbamate-induced Lung Tumors in Mice1

William T. Gunning2, Paula M. Kramer, Vernon E. Steele and Michael A. Pereira

Department of Pathology, Medical College of Ohio, Toledo, Ohio 43614 [W. T. G., P. M. K., M. A. P.], and Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892 [V. E. S.]

5-Leukotriene pathway inhibitors, Accolate, MK-886, and Zileuton, were evaluated as chemopreventive agents in female strain A mice. The mice were administered by injection vinyl carbamate (2 x 16 mg/kg) to induce lung tumors. Two weeks later, they received in their diet Accolate (270 and 540 mg/kg), MK-886 (30 mg/kg), Zileuton (600 and 1200 mg/kg), or combinations containing the lower concentration of two agents. Thirteen weeks later, Accolate, Zileuton (only the high concentration), and combinations of Zileuton with either Accolate or MK-886 reduced lung tumor multiplicity. At week 43, MK-886, Accolate, and Zileuton reduced lung tumor multiplicity by 37.8, 29.5, and 28.1%, respectively. They also decreased the size of the tumors and the yield of carcinomas. These results demonstrate that leukotriene inhibitors prevent lung tumors and slow the growth and progression of adenomas to carcinoma; leukotriene inhibitors warrant further consideration for potential use in humans.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
K. Liby, C. C. Black, D. B. Royce, C. R. Williams, R. Risingsong, M. M. Yore, X. Liu, T. Honda, G. W. Gribble, W. W. Lamph, et al.
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis
Mol. Cancer Ther., May 1, 2008; 7(5): 1251 - 1257.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
P.B. Myrdal, K. Karlage, P.J. Kuehl, B.S. Angersbach, B.A. Merrill, and P.D. Wightman
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation
Carcinogenesis, May 1, 2007; 28(5): 957 - 961.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. S. Alyaqoub, L. Tao, P. M. Kramer, V. E. Steele, R. A. Lubet, W. T. Gunning, and M. A. Pereira
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT)
Carcinogenesis, January 1, 2007; 28(1): 124 - 129.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. S. Alyaqoub, L. Tao, P. M. Kramer, V. E. Steele, R. A. Lubet, W. T. Gunning, and M. A. Pereira
Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (ZarnestraMT)
Carcinogenesis, December 1, 2006; 27(12): 2442 - 2447.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
Z. Sun, S. Sood, N. Li, D. Ramji, P. Yang, R. A. Newman, C. S. Yang, and X. Chen
Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors
Carcinogenesis, September 1, 2006; 27(9): 1902 - 1908.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Li, S. Sood, S. Wang, M. Fang, P. Wang, Z. Sun, C. S. Yang, and X. Chen
Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib
Clin. Cancer Res., March 1, 2005; 11(5): 2089 - 2096.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
X. Chen, S. Wang, N. Wu, S. Sood, P. Wang, Z. Jin, D. G. Beer, T. J. Giordano, Y. Lin, W.-c. J. Shih, et al.
Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis
Clin. Cancer Res., October 1, 2004; 10(19): 6703 - 6709.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. M. Meyer, L. D. Dwyer-Nield, G. J. Hurteau, R. L. Keith, E. O'Leary, M. You, J. V. Bonventre, R. A. Nemenoff, and A. M. Malkinson
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2
Carcinogenesis, August 1, 2004; 25(8): 1517 - 1524.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.